Lourenco Sofia, Teixeira Vitor H, Kalber Tammy, Jose Ricardo J, Floto R Andres, Janes Sam M
Lungs for Living Research Centre, Division of Medicine, University College London, London WC1E 6JF, United Kingdom;
Lungs for Living Research Centre, Division of Medicine, University College London, London WC1E 6JF, United Kingdom; University College London Centre of Advanced Biomedical Imaging, University College London, London WC1E 6DD, United Kingdom;
J Immunol. 2015 Apr 1;194(7):3463-74. doi: 10.4049/jimmunol.1402097. Epub 2015 Feb 23.
Mesenchymal stromal cells (MSCs) are inherently tumor homing and can be isolated, expanded, and transduced, making them viable candidates for cell therapy. This tumor tropism has been used to deliver anticancer therapies to various tumor models. In this study, we sought to discover which molecules are the key effectors of human MSC tumor homing in vitro and using an in vivo murine model. In this study, we discover a novel role for macrophage migration inhibitory factor (MIF) as the key director of MSC migration and infiltration toward tumor cells. We have shown this major role for MIF using in vitro migration and invasion assays, in presence of different receptor inhibitors and achieving a drastic decrease in both processes using MIF inhibitor. Additionally, we demonstrate physical interaction between MIF and three receptors: CXCR2, CXCR4, and CD74. CXCR4 is the dominant receptor used by MIF in the homing tumor context, although some signaling is observed through CXCR2. We demonstrate downstream activation of the MAPK pathway necessary for tumor homing. Importantly, we show that knockdown of either CXCR4 or MIF abrogates MSC homing to tumors in an in vivo pulmonary metastasis model, confirming the in vitro two-dimensional and three-dimensional assays. This improved understanding of MSC tumor tropism will further enable development of novel cellular therapies for cancers.
间充质基质细胞(MSCs)具有内在的肿瘤归巢特性,能够被分离、扩增和转导,使其成为细胞治疗的可行候选者。这种肿瘤嗜性已被用于将抗癌疗法递送至各种肿瘤模型。在本研究中,我们试图发现哪些分子是体外和使用体内小鼠模型时人MSCs肿瘤归巢的关键效应因子。在本研究中,我们发现巨噬细胞迁移抑制因子(MIF)作为MSCs向肿瘤细胞迁移和浸润的关键导向因子具有新的作用。我们使用体外迁移和侵袭试验,在存在不同受体抑制剂的情况下,以及使用MIF抑制剂使这两个过程急剧减少,证明了MIF的这一主要作用。此外,我们证明了MIF与三种受体:CXCR2、CXCR4和CD74之间的物理相互作用。CXCR4是MIF在肿瘤归巢背景中使用的主要受体,尽管通过CXCR2也观察到了一些信号传导。我们证明了肿瘤归巢所必需的MAPK途径的下游激活。重要的是,我们表明在体内肺转移模型中,敲低CXCR4或MIF均可消除MSCs向肿瘤的归巢,这证实了体外二维和三维试验的结果。对MSCs肿瘤嗜性的这种更好理解将进一步推动癌症新型细胞疗法的开发。